Brief: Innovation Pharmaceuticals Announces Pre-Ind Meeting Request Granted By FDA For The Study Of Brilacidin For The Treatment Of Covid-19
02/10/2020 15:02
Oct 2 (Reuters) - Innovation Pharmaceuticals Inc IPIX.PK :
* INNOVATION PHARMACEUTICALS ANNOUNCES PRE-IND MEETING
REQUEST
GRANTED BY FDA FOR THE STUDY OF BRILACIDIN FOR THE TREATMENT OF
COVID-19
Source text for Eikon: ID:nGNX8dNY4W
Further company coverage: IPIX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review